Monte Rosa Therapeutics, Inc.
GLUE · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $12,768 | $23,194 | $84,929 | $60,647 |
| % Growth | -45% | -72.7% | 40% | – |
| Cost of Goods Sold | $2,095 | $0 | $0 | $0 |
| Gross Profit | $10,673 | $23,194 | $84,929 | $60,647 |
| % Margin | 83.6% | 100% | 100% | 100% |
| R&D Expenses | $34,583 | $30,653 | $32,190 | $38,866 |
| G&A Expenses | $0 | $8,095 | $8,703 | $8,777 |
| SG&A Expenses | $9,065 | $8,095 | $8,703 | $8,777 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $43,648 | $38,748 | $40,893 | $47,643 |
| Operating Income | -$32,975 | -$15,554 | $44,036 | $13,004 |
| % Margin | -258.3% | -67.1% | 51.9% | 21.4% |
| Other Income/Exp. Net | $2,717 | $4,458 | $3,671 | $2,597 |
| Pre-Tax Income | -$30,258 | -$11,096 | $47,707 | $15,601 |
| Tax Expense | -$3,177 | $1,199 | $822 | $2,164 |
| Net Income | -$27,081 | -$12,295 | $46,885 | $13,437 |
| % Margin | -212.1% | -53% | 55.2% | 22.2% |
| EPS | -0.33 | -0.15 | 0.57 | 0.22 |
| % Growth | -120% | -126.3% | 159.1% | – |
| EPS Diluted | -0.33 | -0.15 | 0.57 | 0.22 |
| Weighted Avg Shares Out | 82,398 | 82,187 | 82,149 | 61,437 |
| Weighted Avg Shares Out Dil | 82,398 | 82,187 | 82,956 | 61,437 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2,746 | $3,068 | $3,439 | $2,595 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $2,095 | $2,125 | $2,048 | $2,061 |
| EBITDA | -$28,163 | -$13,429 | $46,084 | $15,065 |
| % Margin | -220.6% | -57.9% | 54.3% | 24.8% |